Longboard Pharmaceuticals Inc. was acquired by Lundbeck in December 2024. LBPH no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Lundbeck, and their dates may not have been updated since.
Clinical trial readout dates for Longboard Pharmaceuticals Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is December 2026.